Checkpoint Therapeutics Inc (OQ:CKPT)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 95 SAWYER ROAD, SUITE 110
WALTHAM MA 02453
Tel: 1-617-4307577
Website: https://checkpointtx.com
IR: See website
<
Key People
Michael S. Weiss
Chairman of the Board
James F. Oliviero
President, Chief Executive Officer, Director
William Garrett Gray
Chief Financial Officer, Treasurer, Corporate Secretary
Business Overview
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company that is focused on the acquisition, development and commercialization of treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, which is an anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute (Dana-Farber) in an ongoing global, open-label, multicohort Phase I clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) intended to support one or more applications for marketing approval. In addition, it is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, which is an epidermal growth factor receptor (EGFR) inhibitor as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).
Financial Overview
For the fiscal year ended 31 December 2023, Checkpoint Therapeutics Inc revenues decreased 46% to $103K. Net loss decreased 17% to $51.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 13% to $42.4M (expense), Gain (loss) on common stock warrant liab increase from $4.5M (expense) to $217K (income).
Employees: 23 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $67.87M as of Dec 31, 2023
Annual revenue (TTM): $0.10M as of Dec 31, 2023
EBITDA (TTM): -$52.15M as of Dec 31, 2023
Net annual income (TTM): -$51.85M as of Dec 31, 2023
Free cash flow (TTM): -$47.59M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 35,686,279 as of Mar 19, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.